Pasithea Therapeutics is a biotechnology company at the forefront of developing therapies for central nervous system (CNS) disorders. Leveraging expertise in neuroscience and pharmacology, Pasithea is advancing new molecular entities to treat conditions such as Amyotrophic Lateral Sclerosis (ALS), multiple sclerosis, and neurofibromatosis type 1. Their lead candidate, PAS-004, is a next-generation macrocyclic MEK inhibitor currently in Phase 1 clinical trials for advanced cancers. Committed to addressing unmet medical needs, Pasithea integrates immunology and neuroscience to create novel therapeutics and predictive biomarkers for psychiatric and neurological diseases.